A Pilot Phase II Study With BRENTUXIMAB VEDOTIN as Pre-ASCT Induction Therapy in Relapsed/Refractory Hodgkin's Lymphoma Patients Non Responding to IGEV Salvage Treatment
Phase of Trial: Phase II
Latest Information Update: 15 Feb 2018
Price : $35 *
At a glance
- Drugs Brentuximab vedotin (Primary)
- Indications Hodgkin's disease
- Focus Therapeutic Use
- 15 Feb 2018 Last checked against European Clinical Trials Database record.
- 08 Feb 2018 Status changed from active, no longer recruiting to completed.
- 16 Aug 2016 Status changed from recruiting to active, no longer recruiting.